GeNeuro SA

GEM

Company Profile

  • Business description

    GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).

  • Contact

    3 chemin du Pre-Fleur
    Plan-les-Ouates
    Geneva1228
    CHE

    T: +41 225524800

    https://www.geneuro.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    19

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,820.306.40-0.07%
CAC 407,829.2972.96-0.92%
DAX 4024,255.31201.50-0.82%
Dow JONES (US)44,357.15293.49-0.66%
FTSE 1008,941.1234.54-0.38%
HKSE24,139.57111.200.46%
NASDAQ20,633.953.290.02%
Nikkei 22539,569.6876.68-0.19%
NZX 50 Index12,686.6873.52-0.58%
S&P 5006,263.9116.55-0.26%
S&P/ASX 2008,580.109.10-0.11%
SSE Composite Index3,510.180.500.01%

Market Movers